Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells
- 1 September 1990
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 26 (5), 340-342
- https://doi.org/10.1007/bf02897289
Abstract
4-Demethoxydaunorubicin (4-DMDR) and its major metabolite 4-demethoxy-13-hydroxydaunorubicin (4-DMDRol) were investigated for their cytotoxicity and mode of action against human leukemic cells. The drug and its metabolite appeared to be equally potent as both inhibitors of cell proliferation and inducers of DNA double-strand breaks in the OCI AML-3 cell line and cells derived directly from patients with acute myeloid leukemia (AML). This suggests that 4-DMDRol plays an important role in the antileukemic activity of 4-DMDR.Keywords
This publication has 11 references indexed in Scilit:
- Pharmacokinetics of 4-demethoxydaunorubicin in cancer patientsCancer Chemotherapy and Pharmacology, 1990
- Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorubicin in a human colon adenocarcinoma cell line (LoVo)Biochemical Pharmacology, 1989
- Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients.1987
- Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.1987
- Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.1987
- Clonogenic cells in acute myeloblastic leukemia.1986
- Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycinClinical Pharmacology & Therapeutics, 1986
- SINGLE-STRAND DNA BREAKS INDUCED BY CHROMOPHORE-MODIFIED ANTHRACYCLINES IN P388 LEUKEMIA-CELLS1986
- SYNTHESIS AND ANTITUMOR ACTIVITY OF 4-DEMETHOXYDAUNORUBICIN, 4-DEMETHOXY-7,9-DIEPIDAUNORUBICIN, AND THEIR BETA-ANOMERS1976
- Human bone marrow colony growth in agar‐gelJournal of Cellular Physiology, 1970